- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- PANACEA BIOTECH - MYLAN (US)
PANACEA BIOTECH vs MYLAN (US) - Comparison Results
PANACEA BIOTECH 
Change
Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 PANACEA BIOTECH  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| PANACEA BIOTECH Mar-14 |
MYLAN Dec-14 |
PANACEA BIOTECH/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 149 | 4,285 | - | |
| Low | Rs | 82 | 3,019 | - | |
| Sales per share (Unadj.) | Rs | 84.1 | 1,466.8 | - | |
| Earnings per share (Unadj.) | Rs | -18.3 | 176.7 | - | |
| Cash flow per share (Unadj.) | Rs | -6.7 | 284.4 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 83.7 | 729.1 | - | |
| Shares outstanding (eoy) | m | 61.25 | 378.37 | - | |
| Bonus/Rights/Conversions | - | OI | - | ||
| Price / Sales ratio | x | 1.4 | 2.5 | 55.1% | |
| Avg P/E ratio | x | -6.3 | 20.7 | -30.5% | |
| P/CF ratio (eoy) | x | -17.2 | 12.8 | -134.3% | |
| Price / Book Value ratio | x | 1.4 | 5.0 | 27.5% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 7,074 | 1,381,812 | 0.5% | |
| No. of employees | `000 | 2.8 | 25.0 | 11.0% | |
| Total wages/salary | Rs m | 1,449 | 0 | - | |
| Avg. sales/employee | Rs Th | 1,874.1 | 22,199.6 | 8.4% | |
| Avg. wages/employee | Rs Th | 527.0 | 0 | - | |
| Avg. net profit/employee | Rs Th | -407.7 | 2,674.3 | -15.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,154 | 554,991 | 0.9% | |
| Other income | Rs m | 100 | -3,235 | -3.1% | |
| Total revenues | Rs m | 5,254 | 551,756 | 1.0% | |
| Gross profit | Rs m | -766 | 138,029 | -0.6% | |
| Depreciation | Rs m | 711 | 40,762 | 1.7% | |
| Interest | Rs m | 1,503 | 23,939 | 6.3% | |
| Profit before tax | Rs m | -2,881 | 70,093 | -4.1% | |
| Minority Interest | Rs m | 11 | -288 | -3.8% | |
| Prior Period Items | Rs m | -6 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 1,771 | 0 | - | |
| Tax | Rs m | 17 | 2,947 | 0.6% | |
| Profit after tax | Rs m | -1,121 | 66,858 | -1.7% | |
| Gross profit margin | % | -14.9 | 24.9 | -59.8% | |
| Effective tax rate | % | -0.6 | 4.2 | -13.9% | |
| Net profit margin | % | -21.8 | 12.0 | -180.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,810 | 487,910 | 0.8% | |
| Current liabilities | Rs m | 8,365 | 381,448 | 2.2% | |
| Net working cap to sales | % | -88.4 | 19.2 | -460.8% | |
| Current ratio | x | 0.5 | 1.3 | 35.6% | |
| Inventory Days | Days | 156 | 78 | 199.4% | |
| Debtors Days | Days | 67 | 107 | 62.7% | |
| Net fixed assets | Rs m | 14,480 | 128,396 | 11.3% | |
| Share capital | Rs m | 61 | 19,626 | 0.3% | |
| Net worth | Rs m | 5,127 | 275,885 | 1.9% | |
| Long term debt | Rs m | 5,832 | 412,145 | 1.4% | |
| Total assets | Rs m | 19,433 | 1,111,240 | 1.7% | |
| Interest coverage | x | -0.9 | 3.9 | -23.3% | |
| Debt to equity ratio | x | 1.1 | 1.5 | 76.1% | |
| Sales to assets ratio | x | 0.3 | 0.5 | 53.1% | |
| Return on assets | % | 2.0 | 8.2 | 24.0% | |
| Return on equity | % | -21.9 | 24.2 | -90.2% | |
| Return on capital | % | 3.6 | 13.6 | 26.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 599 | 72,954 | 0.8% | |
| From Investments | Rs m | -438 | -57,534 | 0.8% | |
| From Financial Activity | Rs m | -303 | -19,223 | 1.6% | |
| Net Cashflow | Rs m | -141 | -3,803 | 3.7% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.89 Rs / USD
Compare PANACEA BIOTECH With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare PANACEA BIOTECH With: ABBOTT INDIA FDC LTD. CADILA HEALTHCARE IPCA LABS PFIZER
|
| |
Today's Market
Indian Indices End Week Strong, Pharma Stocks Show Uptick(Pre-Open)
On Friday, share markets in India opened on a positive note and ended the day in green after a volatile day of trading.
Related Views On News
PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)
Jun 20, 2018 | Updated on Jun 20, 2018For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Eris Lifesciences Limited (IPO)
Jun 15, 2017Exposure to high margin specialty products offers promising growth prospects.
More Views on NewsMost Popular
These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)
Nov 9, 2018All blue chip companies are large caps but all large caps are not blue chips.
Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)
Nov 6, 2018If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.
This Was a Large Cap. But Was It Safe?(Chart Of The Day)
Nov 9, 2018Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.
Why the Realty Sector's Recovery Has Been Delayed(Sector Info)
Nov 15, 2018NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?
Does it Make Sense to Invest in Offshore Funds?(Outside View)
Nov 6, 2018Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.
More|
| |
PANACEA BIOTECH SHARE PRICE
Nov 16, 2018 (Close)
TRACK PANACEA BIOTECH
- Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PANACEA BIOTECH
PANACEA BIOTECH - PIRAMAL ENTERPRISES COMPARISON
COMPARE PANACEA BIOTECH WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.